0001209191-24-001537.txt : 20240112
0001209191-24-001537.hdr.sgml : 20240112
20240112170810
ACCESSION NUMBER: 0001209191-24-001537
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20240110
FILED AS OF DATE: 20240112
DATE AS OF CHANGE: 20240112
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Readnour Robin Shane
CENTRAL INDEX KEY: 0001914883
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41331
FILM NUMBER: 24532749
MAIL ADDRESS:
STREET 1: 3835 CLEGHORN AVENUE, SUITE 300
CITY: NASHVILLE
STATE: TN
ZIP: 37215
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AN2 Therapeutics, Inc.
CENTRAL INDEX KEY: 0001880438
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 820606654
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1800 EL CAMINO REAL, SUITE D
CITY: MENLO PARK
STATE: CA
ZIP: 94027
BUSINESS PHONE: (650) 331-9090
MAIL ADDRESS:
STREET 1: 1800 EL CAMINO REAL, SUITE D
CITY: MENLO PARK
STATE: CA
ZIP: 94027
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2024-01-10
0
0001880438
AN2 Therapeutics, Inc.
ANTX
0001914883
Readnour Robin Shane
C/O AN2 THERAPEUTICS, INC.
1800 EL CAMINO REAL, SUITE D
MENLO PARK
CA
94027
1
0
0
0
1
Common Stock
2024-01-10
4
S
0
1869
21.93
D
415494
I
See footnotes
Common Stock
2024-01-10
4
S
0
1800
21.92
D
485792
I
See footnotes
The reported sale of 1,869 shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC Venture Partners 2018, LP ("MGC 2018 LP") on August 30, 2023.
This price represents the weighted average sale price (rounded to the nearest cent) for multiple transactions reported on this line. The prices of the transactions reported on this line ranged from $21.90 to $21.99. Upon request by the Commission staff, the issuer or a security holder of the issuer, the reporting person will undertake to provide full information regarding the number of shares sold at each separate price.
MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC 2018 LP and MGC Venture Partners QP 2018 LP ("MGC 2018 QP"). MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities.
Shares held directly by MGC 2018 LP.
The reported sale of 1,800 shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC 2018 QP on August 30, 2023.
Shares held directly by MGC 2018 QP.
/s/ Jay Ferguson, Attorney-in-Fact for Robin Shane Readnour
2024-01-12
EX-24
2
poa.txt
POA DOCUMENT
POWER OF ATTORNEY
Know all by these presents, that the undersigned hereby constitutes and
appoints each of (i) the Chief Executive Officer of AN2 Therapeutics, Inc., a
Delaware corporation (the "Company"), who is currently Eric Easom, (ii) the
Company's Chief Financial Officer, who is currently Lucy O. Day, (iii) the
Company's Chief Legal Officer and Secretary, who is currently Josh Eizen, and
their respective successors, each of (iv) Kathleen M. Wells, (v) Richard Kim and
(vi) Zuzanna Gruca of Latham & Watkins LLP, and (vii) Jay Ferguson, Vice
President of MGC Venture Partners 2018 GP, LLC, signing individually, with full
power of substitution, as the undersigned's true and lawful attorney-in-fact to:
(1) execute for and on behalf of the undersigned, in the undersigned's
capacity as a director of the Company, Forms 3, 4 and 5 (including amendments
thereto) in accordance with Section 16(a) of the Securities Exchange Act of 1934
and the rules and regulations thereunder and a Form ID, Uniform Application for
Access Codes to File on EDGAR;
(2) do and perform any and all acts for and on behalf of the undersigned
which may be necessary or desirable to complete and execute any such Forms 3, 4
or 5 or Form ID and timely file such forms (including amendments thereto) and
application with the United States Securities and Exchange Commission and any
stock exchange or similar authority; and
(3) take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit to,
in the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in such
attorney-in-fact's
discretion.
The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in
serving in such capacity at the request of the undersigned, are not assuming,
nor is the Company assuming, any of the undersigned's responsibilities to comply
with Section 16 of the Securities Exchange Act of 1934.
The undersigned agrees that each such attorney-in-fact herein may rely
entirely on information furnished orally or in writing by the undersigned to
such attorney-in-fact. The undersigned also agrees to indemnify and hold
harmless the Company and each such attorney-in-fact against any losses, claims,
damages or liabilities (or actions in these respects) that arise out of or are
based upon any untrue statements or omission of necessary facts in the
information provided by the undersigned to such attorney-in fact for purposes of
executing, acknowledging, delivering or filing Forms 3, 4 or 5 (including
amendments thereto) or Form ID and agrees to reimburse the Company and such
attorney-in-fact for any legal or other expenses reasonably incurred in
connection with investigating or defending against any such loss, claim, damage,
liability or action.
This Power of Attorney supersedes any power of attorney previously executed
by the undersigned regarding the purposes outlined in the first paragraph hereof
("Prior Powers of Attorney"), and the authority of the attorneys- in-fact named
in any Prior Powers of Attorney is hereby revoked.
This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4 or 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier (a) revoked by the undersigned in a signed writing delivered to
the foregoing attorneys-in-fact or (b) superseded by a new power of attorney
regarding the purposes outlined in the first paragraph hereof dated as of a
later date.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 11th day of January, 2024.
/s/ Robin Shane Readnour
Robin Shane Readnour